- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03003806
Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study (Advice4U)
Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- Open Label, Parallel , Randomized, Controlled Multicenter Study-The Advice4U Pro Study
The DreaMed Advisor Pro is a software which automatically analyses treatment information, learns patient's needs and accordingly suggests adjustments in insulin dosing. The DreaMed Advisor Pro uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests pump-setting changes for optimization of glucose control
The algorithm is designed as an advisory tool and has three main components:
- A statistical analysis of the insulin pump and sensor data: insulin delivery, bolus-calculator rate of use, sensor glucose variables, hypoglycemic and hyperglycemia patterns.
- Practical recommendations, alert messages based on aforementioned data
- Recommendation for new insulin pump settings: including basal intervals and rate, different carbohydrate ratio according to time of day, correction factor and insulin sensitivity time.
The main goal of the DreaMed Advisor Pro is to improve diabetes management for subjects with Type 1 Diabetes (T1D) by using an innovative Advisor to determine insulin dosing for pump users.
The main objective of the proposed study is to evaluate the safety and efficacy of using the DreaMed Advisor Pro algorithm versus medical guided recommendation to determine insulin dosing for sub-optimal controlled subjects with type 1 diabetes using pump therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hannover, Germany
- Diabetes -Zentrum fuer kinder und jugendliche
-
-
-
-
-
Petach-Tikva, Israel, 49202
- Schnider Children's medical center
-
-
-
-
-
Ljubljana, Slovenia
- University Children's Hospital
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80045-6511
- Barbara Davis Center for Childhood Diabetes
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520-8064
- Yale University School of Medicine
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida College of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center, One Joslin Place
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject with Type 1 diabetes (>1yr since diagnosis)
- Age ≥ 10 years up to 21 years
- HbA1c at inclusion ≥ 7.0% and ≤ 10%
- Insulin infusion pump therapy: "OmniPod®" Insulin pump (insulet Corp., Bedford, "MA", USA) or any Medtronic pump that is comparable with Glooko app for at least 4 months
- BMI Standard Deviation Score (SDS) - below the 97th percentile for age
- Patients willing to follow study instructions (at least 2 capillary blood glucose readings/day, use the bolus-calculator feature of the pump)
- Patient/ parents are required to have minimum computer skills and understanding of navigating the internet
- Patients willing to use dexcom sensor for the study duration
- Patients/ parents will have to have a smart phone (Apple, Android, Windows)
Exclusion Criteria:
- An episode of diabetic ketoacidosis within the month prior to study entry
- Concomitant diseases/ treatment that influence metabolic control
- Any significant diseases /conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety,
- Participation in any other interventional study
- Known or suspected allergy to trial products such as adhesives, tapes, needles. An allergy to contrast medium, use of other active medical devices (such as pacemaker, ICD) and planned imaging examinations (such as MRI).
- Female subject who is pregnant or lactating planning to become pregnant within the planned study duration -Severe hypoglycemia six month prior to enrollment as defined by the American Diabetes Association (ADA) and Endocrine Society as follows: "Severe hypoglycemia is an event requiring assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions". -
- Current use of the following medications: medications that are used to lower blood glucose such as Pramlintide, Metformin and GLP-1 analogs. Beta blockers, glucocorticoids and other medications, which in the judgment of the investigator would be a contraindication to participation in the study (Anticoagulant therapy e.g. Plavix, LMW heparin, Coumadin, Immunosuppressant therapy)
Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus
- Subject has unstable or rapidly progressive renal disease or is receiving dialysis
- Subject has active proliferating retinopathy
- Active gastroparesis
- Patient suffers from an eating disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DreaMed Advisor Pro
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
|
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
|
Active Comparator: Control group-medical guided recommendations
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
|
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of glucose readings within range of 70-180 mg/dl (3.9 to 10 mmol/l).
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Percentage of glucose readings below 54 mg/dl (3.3 mmol/l)
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HbA1c
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Percentage of glucose readings below 70 mg/dl (3.9 mmol/L)
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Percentage of readings below 50 mg/dl (2.8 mmol/L)
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Percentage of readings above 180 mg/dl (10.0 mmol/L)
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Percentage of readings above 240 mg/dl (13.3 mmol/L)
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Area above the curve of glucose glucose level of 180 mg/dl
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Area under the curve of glucose level of 70 mg/dl
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Mean sensor blood glucose
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Glucose variability measured by Standard Deviation
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Number of recommendations for changes in settings per patient
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Number of recommendations for changes in settings per iteration
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Number of physician override Advisor recommendations
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Number of patients overrides of recommendation
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Estimated time duration needed for the physician to give its recommendations
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Device satisfaction questionaire
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Diabetes treatment satisfaction questionnaire
Time Frame: Final visit (week 31)
|
Final visit (week 31)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMC072016ctil
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type1 Diabetes Mellitus
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedType1 Diabetes MellitusUnited States
-
Massachusetts General HospitalCompletedType1 Diabetes MellitusUnited States
-
Universidad Loyola AndaluciaUnknown
-
Jessa HospitalCompleted
-
Eli Lilly and CompanyCompletedA Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)Type1 Diabetes MellitusUnited States
-
AdociaCompleted
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Second Xiangya Hospital of Central South UniversityRecruitingType1 Diabetes Mellitus | Autoimmune DiabetesChina
-
Chinese University of Hong KongRecruiting
Clinical Trials on DreaMed Advisor Pro
-
Rabin Medical CenterCompleted
-
Yale UniversityDreaMedWithdrawn
-
Rabin Medical CenterThe Leona M. and Harry B. Helmsley Charitable Trust; DreaMed DiabetesRecruiting
-
DreaMed DiabetesCompletedDiabetes Mellitus, Type 1 | Insulin-dependent Diabetes MellitusIsrael
-
NORCE Norwegian Research Centre ASHelse Sor-Ost; Sykehuset i Vestfold HFCompletedNeck Pain Musculoskeletal | Back Pain Lower BackNorway
-
Ottawa Hospital Research InstituteNot yet recruitingAirway ExtubationCanada
-
Ottawa Hospital Research InstituteRecruiting
-
Philips HealthcareCompletedClinical AlarmsGermany
-
Philips HealthcareYale UniversityCompletedClinical AlarmsUnited States